



For Immediate Release

January 17, 2021

Acuitas Announces Sponsorship for the Vancouver Athletic Football Club

Vancouver, B.C. – Acuitas Therapeutics is proud to announce a multi-year sponsorship agreement with Vancouver Athletic Football Club (VAFC). This sponsorship will allow the club to expand their training resources and offset costs for equipment and uniforms, Dr. Thomas Madden, President & CEO of Acuitas recently announced.

Said Dr. Madden: “Giving back to the community is extremely important to the Acuitas team. We know how important youth sports is – to the young players and to the community. It teaches teamwork, commitment and, of course, how to lose gracefully and win with humility. We also recognize that youth sports provide an important foundation for a healthy lifestyle.”

“We are excited to welcome Acuitas Therapeutics as a VAFC sponsor,” said VAFC President, Darren Sherbot. “The Acuitas team is demonstrating their commitment to youth sports and the benefits that sports bring to young people. Acuitas’ generous sponsorship helps VAFC deliver on our goals of offering an inclusive, affordable and positive coaching environment for our soccer club.”

About Vancouver Athletic Football Club

Vancouver Athletic Football Club (www.vafc.ca) is one of the largest soccer clubs in the lower mainland. VAFC continues to grow and now has more than 2,800 youth players and is supported by more than 600 volunteer team officials. They deliver year-round soccer programs in Vancouver. VAFC offers a supportive environment, from grass roots to high performance, while promoting the values of sportsmanship, fair play, inclusiveness, diversity and respect.

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally-recognized



capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY[®], which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-